Comparative Pharmacology
Head-to-head clinical analysis: HEPATAMINE 8 versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPATAMINE 8 versus NEPHRAMINE 5 4.
HEPATAMINE 8% vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPATAMINE 8% is a branched-chain amino acid (BCAA) solution that provides leucine, isoleucine, and valine to correct amino acid imbalances in hepatic encephalopathy. It reduces plasma aromatic amino acids (AAA) and increases BCAA, restoring the BCAA/AAA ratio, which decreases false neurotransmitter synthesis in the brain.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion: 125 mL/hr initially, titrate to achieve positive nitrogen balance; typical adult dose: 125 mL/hr to 250 mL/hr via central line, not to exceed 2 g protein equivalent per kg per day.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Variable; amino acids in HEPATAMINE 8% are cleared rapidly (t1/2 ~10-20 minutes for free amino acids) due to endogenous metabolism. In hepatic failure, half-life may be prolonged (patients with cirrhosis: up to 60 minutes for certain amino acids). Clinical context: supports continuous infusion for stable plasma levels.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Renal: negligible as intact amino acids; nitrogen waste (urea) excreted renally (80-90% of infused nitrogen). Biliary/fecal: <5%.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution